Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.

A study published Feb. 25 in Circulation suggests wearables are useful for detecting CV abnormalities like atrial fibrillation, but there’s still a long way to go before they can be trusted for clinical management.

Brain stents seem to be safe and effective in reducing the risk of recurrent stroke in patients who suffer from cholesterol-clogged brain arteries, according to research presented at the American Stroke Association’s International Stroke Conference.

The diabetes drug dulaglutide—sold commercially as Trulicity—has received an expanded indication for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established CVD or CV risk factors.

Mount Sinai has launched an Adult Congenital Heart Disease Center at Mount Sinai Heart in New York in an attempt to streamline CHD care throughout the life cycle.

A secondary analysis of the AUGUSTUS trial confirms earlier findings that treating heart patients with the anticoagulant apixaban results in less major bleeding, hospitalization and death than warfarin, a standard-of-care blood thinner.

The FDA has approved bempedoic acid as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia.

Six barbershops in the Toledo, Ohio, area have implemented CV awareness programs that specifically target black men, CBS affiliate WTOL reported Feb. 14.